, Tracking Stock Market Picks
Enter Symbol:
Depomed, Inc. (DEPO) [hlAlert]

up 725.21 %

Depomed, Inc. (DEPO) rated Buy with price target $9 by Caris & Company

Posted on: Wednesday,  Oct 21, 2009  9:25 AM ET by Caris & Company

Caris & Company rated Buy Depomed, Inc. (NASDAQ: DEPO) on 10/21/2009, when the stock price was $3.49. Since
then, Depomed, Inc. has gained 725.21% as of 01/07/2016's recent price of $28.80.
If you would have followed this Caris & Company's recommendation on DEPO, you would have gained 725.21% of your investment in 2269 days.

Depomed, Inc. (Depomed) is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that are based on oral drug delivery technologies. Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride extended release tablets), which is a once-daily treatment for adults with type 2 diabetes that it commercializes in the United States with Santarus, Inc. (Santarus). ProQuin XR (ciprofloxacin hydrochloride extended release tablets), which is a once-daily treatment for uncomplicated urinary tract infections that Depomed commercializes in the United States with Watson Pharma (Watson).

Caris & Company, an investment bank created by a diverse group of leading Wall Street professionals. We are founded on the basic principle that Wall Street requires a different type of organization: One that offers objective, conflict-free research, acute focus on customer service, broad institutional coverage, and an unwavering commitment to increasing the value of our clients' portfolios. Quite simply, our goal is to generate solid investment ideas for our clients. We offer a unique, differentiated, conflict-free research perspective on large, mid, and small capitalization companies in four growth oriented verticals: Health Care, Technology, Energy, and Consumer.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/21/2009 9:25 AM Buy
3.49 9.00
as of 12/31/2009
1 Week up  78.76 %
1 Month up  77.67 %
3 Months up  66.47 %
1 YTD up  66.47 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy